- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05854303
Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction
September 18, 2023 updated by: Diana L. Snyder, Mayo Clinic
Prospective Evaluation of the Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction (OIED)
The purpose of this study is to evaluate the effect of opioid cessation on opioid-induced esophageal dysfunction (OIED).
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
26
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mariah Robran
- Phone Number: 507-266-3595
- Email: robran.mariah@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients being seen in the Pain Rehabilitation Center for opioid cessation at Mayo Clinic Rochester.
Description
Inclusion Criteria:
- Patients enrolled in the Pain Rehabilitation Center for opioid cessation, with or without esophageal symptoms.
Exclusion Criteria:
- Inability to provide informed consent.
- Patients with previous gastroesophageal surgery or pneumatic dilation.
- Esophageal botulinum toxin injection within the prior 12 months.
- Esophageal stricture
- Achalasia types I and II
- Allergy to Lidocaine or other local anesthetics
- Subjects on anticoagulation
- Bilateral nasal obstruction
- Pregnancy or breast feeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Opioid Cessation
Subjects able to complete opioid cessation.
|
Non-Opioid Cessation
Subjects unable to complete opioid cessation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects to have opioid-induced esophageal dysfunction resolution
Time Frame: 4 weeks
|
Number of subjects to have resolution of opioid-induced esophageal dysfunction
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with dysphagia
Time Frame: 4 weeks
|
Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have dysphagia
|
4 weeks
|
Number of subjects with chest pain
Time Frame: 4 weeks
|
Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have chest pain
|
4 weeks
|
Number of subjects with opioid-induced esophageal dysfunction
Time Frame: 4 weeks
|
Number of subjects that are chronic opioid users presenting to an opioid cessation clinic to have opioid-induced esophageal dysfunction
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Diana Snyder, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 18, 2023
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
May 3, 2023
First Submitted That Met QC Criteria
May 3, 2023
First Posted (Actual)
May 11, 2023
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 18, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-001879
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Opioid-Induced Esophageal Dysfunction
-
Region Örebro CountyCompletedOpioid Induced Pharyngeal and Esophageal DysfunctionSweden
-
Sucampo Pharma Americas, LLCSucampo Pharmaceuticals, Inc.CompletedOpioid-induced Bowel DysfunctionUnited States, Czechia, Germany, Belgium, Poland, Sweden, United Kingdom
-
ShionogiCompletedOpioid Induced Bowel DysfunctionUnited States
-
Temple UniversityAstraZenecaTerminatedOpioid-Induced Disorders | Esophagus DisorderUnited States
-
Sucampo Pharma Americas, LLCSucampo Pharmaceuticals, Inc.CompletedOpioid-Induced Bowel DysfunctionUnited States, Canada
-
Bausch Health Americas, Inc.Completed
-
Kuopio University HospitalCompletedConstipationFinland
-
Istanbul Aydın UniversityIstanbul University; Acibadem UniversityRecruitingOpioid-induced Bowel Dysfunction | Constipation Drug InducedTurkey
-
Sucampo Pharma Americas, LLCCompletedOpioid-Induced Bowel DysfunctionUnited States, Canada
-
Sucampo Pharma Americas, LLCSucampo Pharmaceuticals, Inc.CompletedOpioid-Induced Bowel DysfunctionUnited States, Canada